Clinical trials: Postmenopausal Women With Osteoporosis
Postmenopausal Osteoporosis
Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal Osteoporosis Who Sequentially Completed…
- Trial name
- NCT00577421
- Testing
- risedronate
- Where
- 5 sites in Australia, Italy and 3 more
- Volunteers
- 32 people
- Sponsor
- Warner Chilcott
Osteopenia, Osteoporosis
Low-Dose Hormone Replacement Therapy and Alendronate for Osteoporosis
Osteoporosis, a condition in which bones are fragile and break easily, is a major health problem for postmenopausal women. Research studies have shown that both estrogen/progestin replacement therapy (hormone replacement therapy…
- Trial name
- NCT00000430
- Testing
- Alendronate, Estrogen/progestin therapy
- Where
- United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Osteoporosis, Postmenopausal
Satisfaction and Compliance of Risedronate in PMO
Compare subject satisfaction of once a week dosing of 35 mg Risedronate to once daily dosing of 5 mg Risedronate in postmenopausal osteoporotic women.
- Trial name
- NCT00549965
- Testing
- Risedronate Sodium
- Where
- South Korea
- Volunteers
- 202 people
- Sponsor
- Sanofi
Post Menopausal Osteoporosis
Evaluation of Adherence With Bisphosphonates and Calcium and Vitamin D Supplements in Women With Postmenopausal Osteoporosis
This study aims to evaluate the adherence of patients to combined treatment with bisphosphonates and calcium and vitamin D supplements, which is one of the usual treatments for postmenopausal osteoporosis.
- Trial name
- OSTEOAD (NCT07105163)
- Where
- 20 sites in Spain
- Volunteers
- 230 people
- Sponsor
- Procare Health Iberia S.L.
Postmenopausal, Osteopenia
Effects of Denosumab on the Pharmacokinetics of Etanercept
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis…
- Conditions
- Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
- Trial name
- NCT01294397
- Testing
- Etanercept, Denosumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Osteoporosis in Post-menopausal Women
Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD
Osteoporosis is associated with a high risk of fractures, disability, loss of independence, and excess mortality. Zoledronic acid is an established first-line treatment in Sweden, but many patients at high fracture risk remain at…
- Trial name
- STRONG-HIP (NCT07772609)
- Testing
- Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU
- Where
- 9 sites in Sweden
- Volunteers
- 216 people
- Sponsor
- Sahlgrenska University Hospital
Osteopenia, Osteoporosis
Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral Dose
The primary objective of this study is to compare the urinary excretion of 14C-labeled risedronate and alendronate over 28 days.
- Trial name
- NCT00577850
- Testing
- risedronate, alendronate
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Warner Chilcott
Osteoporosis
Study of MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (MK-0217A-329)
This study will assess the effect of 26 weeks of once-weekly treatment with MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet (Fosamax Plus 70/5600) on serum levels of 25-hydroxyvitamin D [25(OH)D].
- Trial name
- NCT01437111
- Testing
- MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet
- Volunteers
- 200 people
- Sponsor
- Organon and Co
Postmenopausal Osteoporosis
A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®
The Study will be conducted to Compare the Efficacy, Safety, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Enzene Denosumab (ENZ215) and Prolia® in Postmenopausal Women with Osteoporosis.
- Trial name
- NCT05405725
- Testing
- ENZ215, Prolia
- Where
- 48 sites in Bulgaria, Czechia and 5 more
- Volunteers
- 504 people
- Sponsor
- Enzene Biosciences Ltd.
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
This 3 arm study will evaluate renal safety after administration of an intravenous (iv) injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis, at increased risk of renal…
- Trial name
- NCT00503113
- Testing
- ibandronate [Bonviva/Boniva], Alendronate
- Where
- 44 sites in United States, Argentina and 4 more
- Volunteers
- 801 people
- Sponsor
- Hoffmann-La Roche
Osteopenia, Osteoporosis
Effects of Physical Exercise on Postmenopausal Risk Factors in Women With Osteopenia
Menopause usually have a serious impact on a woman's life, associated with negative consequences for health and quality of life.
- Trial name
- ACTLIFE (NCT03959995)
- Testing
- High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT), Wellness
- Where
- Germany
- Volunteers
- 27 people
- Sponsor
- University of Erlangen-Nürnberg Medical School
Osteoporosis
Denosumab Adherence Preference Satisfaction Study
The primary objective is to evaluate the adherence of subjects to subcutaneous (SC) 60 mg denosumab every 6 months (Q6M) treatment compared to oral 70 mg alendronate once a week (QW) treatment at the end of treatment period 1 (12…
- Trial name
- NCT00518531
- Testing
- alendronate, denosumab
- Volunteers
- 250 people
- Sponsor
- Amgen
Breast Cancer, Osteoporosis
Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial
RATIONALE: Learning about the effect of exemestane and anastrozole on bone mineral density in postmenopausal women with primary breast cancer may help plan treatment, decrease the risk of broken bones, and help patients live more…
- Trial name
- NCT00354302
- Testing
- calcium carbonate, calcium citrate, cholecalciferol
- Where
- 13 sites in Canada
- Volunteers
- 497 people
- Sponsor
- NCIC Clinical Trials Group
Postmenopausal Osteoporosis
Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .
evaluate the differences in effectiveness and safety between CMAB807( potential biosimilar) and Prolia(original product)
- Trial name
- NCT04591275
- Testing
- CMAB807 Injection, Prolia®
- Where
- China
- Volunteers
- 278 people
- Sponsor
- Shanghai Biomabs Pharmaceutical Co., Ltd.
Postmenopausal Women Osteoporosis
Post-menopausal Women Osteoporosis(Phase III)
The purpose of this study is to evaluate the efficacy and the safety of Risedronate, cholecalciferol combination tablet in patients with Osteoporosis
- Trial name
- NCT01806792
- Testing
- risedronate combine, Risedronate
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Post-Menopausal Osteoporosis
A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis
To evaluate the noninferiority of a 6-month treatment with 210 mg romosozumab at 90 mg/mL administered subcutaneously (SC) once a month (QM) in postmenopausal women with osteoporosis either by healthcare provider (HCP)…
- Trial name
- NCT03432533
- Testing
- romosozumab HCP administration with PFS, romosozumab self-administration with AI/Pen
- Where
- 46 sites in United States, Poland and 1 more
- Volunteers
- 283 people
- Sponsor
- Amgen
Osteoporosis
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
1. The study will assess the safety and tolerability of a single-infusion of zoledronic acid 5 mg administered in a private medical practice setting by a nurse provided by a nationwide infusion service.
- Trial name
- LISA (NCT00745485)
- Testing
- zoledronic acid
- Where
- 14 sites in Australia
- Volunteers
- 186 people
- Sponsor
- Novartis Pharmaceuticals
Osteoporosis in Post-menopausal Women
Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures
The aim of this clinical trial is to investigate the effectiveness of romosozumab started without stopping denosumab in patients diagnosed with postmenopausal osteoporosis with a very high risk of fragility fractures and who is…
- Trial name
- MORD (NCT06720350)
- Testing
- Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia)
- Where
- Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Marmara University
Osteoporosis
Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
This clinical trial was multicenter, randomized, double-blind, placebo-controlled, parallel, phase III bridge study.
- Trial name
- NCT06154187
- Testing
- PBK_L2201
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Pharmbio Korea Co., Ltd.
Osteoporosis
An Investigation Into the Short Term Effect of APOMINE in Patients With Osteoporosis or Low Bone Mass
Osteoporosis affects millions of postmenopausal women in the USA. The current approved treatments are all drugs that prevent bone loss and possibly result in small gains in bone mass.
- Trial name
- NCT00078026
- Testing
- Apomine
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company